Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.
about
Digitalis for treatment of heart failure in patients in sinus rhythmPhosphodiesterase III inhibitors for heart failureDigitalis for treatment of heart failure in patients in sinus rhythmNovel role of phosphodiesterase inhibitors in the management of end-stage heart failureBeneficial haemodynamic effects of insulin in chronic heart failureInotropes do not increase mortality in advanced heart failureHeart failure: Part IIThe therapeutic potential of dopamine modulators on the cardiovascular and renal systems.Understanding cardiac output.Heart failure as an inflammatory condition: potential role for androgens as immune modulators."Value" of improved treadmill exercise capacity: lessons from a study of rate responsive pacing.Drug therapy in chronic heart failure.Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.Quality-of-life measurement in chronic heart failure: do we take account of the patient perspective?A Pharmacokinetic and Pharmacodynamic Study of Intravenous Levosimendan in Healthy Chinese Volunteers and Ethnic ComparisonsModulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment.Achieving appropriate endpoints in heart failure trials: the PRIME-II protocol. The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy.Recent advances. Cardiology.Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsQuality of life in heart failure treated with enoximone.Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.Indicators of myocardial dysfunction and quality of life, one year after acute infarction.Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy.
P2860
Q24194992-A494067F-7219-4B73-ACBD-C3337D7CB135Q24244978-6286FDBD-EE6E-4A0E-BB84-A5EC79ED4825Q24247158-4C640C8F-3F89-436F-B540-CEF202608165Q26741100-5F989F2C-7448-477A-A9F5-3D94721C6A26Q28362649-F2AF3610-85E1-4557-8B4F-89066E2D73B6Q33685748-CC229FF1-1B6E-43A8-88A6-07300A07F63FQ33708950-4D4D2F88-53F3-4A5B-A95C-641611E7A3D7Q34628662-BB40DD01-A416-4BED-8460-98D7D36D36E6Q34821267-E7F786B0-427B-4390-AA95-9E2B51043CFFQ35009689-7C903657-706E-4B8A-BB33-CB0E8E4F9AA2Q35369340-F1AC9C26-9502-4803-923C-0434476E7DF9Q35518236-713F169C-D64C-4C6E-95B0-266E01D4771BQ35958237-9B9B4C91-A27E-47C4-A54D-D1C4A541BC1CQ36142228-66BA10C0-3D0B-4488-88AD-06DE30CBDE5FQ36721821-4CA2BE36-D438-4281-9367-8029B570D25AQ36848480-9089E7C4-A939-4B7D-9A86-1ECAF246579DQ37331786-B5FF3B10-2C9E-40DD-9CF9-AA230A851597Q38067300-881B6EDE-37CD-4540-BF67-806D6AE8DF78Q40753022-D045BBBE-B227-4A91-B559-E5848032996DQ41744467-462641ED-1C22-4CD7-B592-46BB86FD5CFEQ41859441-7F2E6018-BD7E-4D72-BFCB-141FEEB99A74Q42393565-0A006F85-02B4-468A-AC5B-C0125DEA14BDQ43239177-62442342-9056-4D7E-B5AA-C7BE117F5EBAQ48464139-E7B2829A-4512-4040-BB57-B18026CCB407Q48681954-67F09D3B-38AB-4029-83AE-A064E457C92AQ49300240-62973D74-6344-41BC-9DDA-7C367F12B4AA
P2860
Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@ast
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@en
type
label
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@ast
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@en
prefLabel
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@ast
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@en
P2860
P356
P1476
Treatment of severe heart fail ...... mone. Enoximone Investigators.
@en
P2093
P2860
P304
P356
10.1136/HRT.72.3.226
P577
1994-09-01T00:00:00Z